Replies to post #336409 on Avid Bioservices Inc (CDMO)

[EndoTarget]

WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.

“I am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,” said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. “Her track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our unique RNA-based biomarker approach, which has the potential to bring precision medicine to more cancer patients in need of better treatments.”

[rome75]

I counted 3 trials with Merck and another with radiation on clinical trials . Gov. Type in bavituximab.

Phase 2.

You never know

Still holding strong been a long time

[EndoTarget]

https://clinicaltrials.gov/ct2/show/NCT04099641

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda.